Joint Formulary & PAD

Tofacitinib - Rheumatoid arthritis

You are here : Home > Formulary Search > Tofacitinib - Rheumatoid arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
ICB
NICE
SPC
Restrictions / Comments :

Documentation

Policy Statement
Tofacitinib for moderate to severe Rheumatoid Arthritis - Policy Statement PCN 298-2017 - December 2
NICE Technology Appraisal
NICE TA480 - Tofacitinib for moderate to severe Rheumatoid Arthritis
Evidence Review
Tofacitinib for moderate to severe Rheumatoid Arthritis - NICE briefing paper - December 2017
Webpage
MHRA risk warning - JAK inhibitors - Apr 23

PAD Profile

ChemicalSubstance :
Tofacitinib
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, DMARD, bDmard, Disease modulating, Rheumatology, cytokine modulator, Protein Kinase inhibitor, Jak inhibitor, Janus Kinase
Brand Names Include :
Xeljanz
Important Information :
Severe disease only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Rheumatoid arthritis
Supporting Documents :
4

Committee Recommendations (1)

18 Dec 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends tofactinib as a treatment option for the treatment of moderate to severe Rheumatoid Arthritis in line with NICE TA480.

Prescribing will be by hospital specialists only, in line with NICE TA480 using Blueteq initiation and continuation forms. Tofacitinib will be considered RED on the traffic light system.

Other Indications

Below are listed other indications that Tofacitinib is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Rheumatoid arthritis.